Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: D1 - Dexmedetomidinelow low dose group: Patients will receive DEX 0.2 µg/kg/h infusion diluted to 50 ml for 24 hours
Intervention2: D2 -Standard Dexmedetomidine Dose Group: Patients wi
Sponsors
Department of Anaesthesia and Intensive Care
Eligibility
Inclusion criteria
Inclusion criteria: All patients in age group 18-65 years with good grade Aneurysmal SAH (Hunt & Hess grade-1 & 2 or WFNS grade-1 & 2), coming for Aneurysmal clipping or coiling
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, lung, liver, kidney, or metabolic diseases 2. Patients who had severe bradycardia or acute or chronic arrhythmias at presentation 3. Poor grade Aneurysmal SAH (Hunt & Hess grade-3-5 and WFNS grade 3-5) 4. Known allergy to dexmedetomidine 5. Patients with known Psychiatric disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effects of different doses of Dexmedetomidine (0.2µg/kg & 0.5µg/kg) vs placebo on neurological outcome of Aneurysmal SAH patients at discharge, defined as a Modified Rankin Scale (mRS) score of 0â??2.Timepoint: At discharge | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of S100β protein and NSE (Neuron Specific Enolase) levels at Pre-op and Post op- 48hrs (Day 2) & Post-op Day 5.Timepoint: Immediate Preoperative, 48 hours post intervention, and postoperative Day 5;Evaluation of autoregulatory status changes and Delayed Cerebral Ischemia (DCI) of patient by trans-cranial dopplerTimepoint: Preoperatively, Postop Day 1-5 daily once;Extended Glasgow Outcome Scale scoreTimepoint: At 3 months post discharge;Observation of effect of DEX infusion on Peri-operative patient hemodynamics (Heart rate and MAP)Timepoint: At 5 min interval throughout intra-operative period | — |
Countries
India
Contacts
Public ContactSomsubhra Pal
PGIMER, Chandigarh
Outcome results
None listed